ReviewOncology reports2026
Unveiling the molecular landscape: Long non-coding RNAs in neuroblastoma (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is a prevalent malignant tumor in pediatric populations, accounting for 10-15% of childhood cancer-related deaths. Standard treatments include surgery, radiotherapy and chemotherapy; however, in recent years, immunotherapy and targeted therapies have also demonstrated encouraging outcomes, particularly for high-risk NB cases. Despite these advances, more than one-third of patients either fail to respond to immunotherapy or eventually develop therapeutic resistance, highlighting the need to further explore the molecular mechanisms driving NB and to develop novel therapeutic approaches. Notably, dysregulated long non-coding RNA (lncRNA) expression is closely associated with NB prognosis, early diagnosis and therapeutic responsiveness. The present review systematically summarizes the molecular mechanisms by which lncRNAs contribute to NB development and progression, and provides an updated overview of their emerging clinical applications as diagnostic, prognostic and therapeutic targets. The current study may offer valuable insights into the future development of lncRNA-based precision diagnostic and therapeutic strategies for NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.